QurAlis Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 87

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $20M

  • Investors
  • 19

QurAlis General Information

Description

Developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets. The company's proprietary platforms and biomarkers offer the design and development of drugs that act directly on disease-causing genetic alterations, advancing a robust precision medicine pipeline with therapeutic candidates that modify severe disease pathology in defined patient populations based on both disease-causing genetic mutation and clinical biomarkers, enabling medical professionals to halt disease progression and significantly improve outcomes.

Contact Information

Website
www.quralis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 35 Cambridgepark Drive
  • Suite 300
  • Cambridge, MA 02140
  • United States
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 35 Cambridgepark Drive
  • Suite 300
  • Cambridge, MA 02140
  • United States

QurAlis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

QurAlis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 04-Sep-2025 $20M Completed Clinical Trials - Phase 1
8. Secondary Transaction - Private Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 09-Mar-2023 Completed Clinical Trials - Phase 1
6. Accelerator/Incubator 01-Jan-2022 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A1) 13-May-2020 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 19-Nov-2018 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view QurAlis’s complete valuation and funding history, request access »

QurAlis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A1
Series A3 980,744 $0.000100 $3.06 $3.06 1x $3.06 1.69%
Series A2 4,145,771 $0.000100 $2.22 $2.22 1x $2.22 7.12%
To view QurAlis’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

QurAlis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative dis
Therapeutic Devices
Cambridge, MA
87 As of 2026

San Francisco, CA
 

Bothell, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

QurAlis Competitors (9)

One of QurAlis’s 9 competitors is Verge Labs, a Venture Capital-Backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Verge Labs Venture Capital-Backed San Francisco, CA
LeonaBio Formerly VC-backed Bothell, WA
Amylyx Pharmaceuticals Formerly VC-backed Cambridge, MA
Biohaven Formerly VC-backed New Haven, CT
Xenon Pharmaceuticals Formerly VC-backed Burnaby, Canada
You’re viewing 5 of 9 competitors. Get the full list »

QurAlis Patents

QurAlis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026080735-A1 Functionalized tetrahydrofuran intermediate and synthesis thereof Pending 09-Oct-2024
WO-2026080323-A1 Treatment of neurological diseases using modulators of unc13a gene transcripts Pending 09-Oct-2024
EP-4720083-A1 Functionalized tetrahydrofuran intermediate and synthesis thereof Pending 02-Jun-2023
WO-2024249886-A1 Functionalized tetrahydrofuran intermediate and synthesis thereof Inactive 02-Jun-2023
AU-2024283557-A1 Modified unc13a oligonucleotides Pending 02-Jun-2023 A61K31/712
To view QurAlis’s complete patent history, request access »

QurAlis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

QurAlis Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
ALS Investment Fund Venture Capital Minority
EQT Life Sciences Venture Capital Minority
Pimlico Pond Investments Family Office Minority
Sanofi Ventures Corporate Venture Capital Minority
Termeer Institute Accelerator/Incubator
You’re viewing 5 of 19 investors. Get the full list »

QurAlis FAQs

  • When was QurAlis founded?

    QurAlis was founded in 2016.

  • Where is QurAlis headquartered?

    QurAlis is headquartered in Cambridge, MA.

  • What is the size of QurAlis?

    QurAlis has 87 total employees.

  • What industry is QurAlis in?

    QurAlis’s primary industry is Therapeutic Devices.

  • Is QurAlis a private or public company?

    QurAlis is a Private company.

  • What is QurAlis’s current revenue?

    The current revenue for QurAlis is .

  • How much funding has QurAlis raised over time?

    QurAlis has raised $158M.

  • Who are QurAlis’s investors?

    ALS Investment Fund, EQT Life Sciences, Pimlico Pond Investments, Sanofi Ventures, and Termeer Institute are 5 of 19 investors who have invested in QurAlis.

  • Who are QurAlis’s competitors?

    Verge Labs, LeonaBio, Amylyx Pharmaceuticals, Biohaven, and Xenon Pharmaceuticals are some of the 9 competitors of QurAlis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process